anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
This is an outpatient study that requires a screening visit and two study days in the Vanderbilt Clinical Research Center. Subjects will be asked to stop taking any medications for high blood pressure for at least 2 weeks prior to the study. Subjects will receive intravenous angiotensin-(1-7) or saline infusion on two separate study days, with each study day lasting approximately four hours. There will be at least one week of washout between study days. On each study day, subjects will be instrumented with two intravenous catheters (one for blood sampling and one for drug infusion), arm and finger blood pressure cuffs, and sticky patches to measure heart rate throughout the study. The investigators will take baseline measurements of blood pressure and heart rate and collect blood samples. The investigators will also perform a rebreathing test to measure the heart's pumping capacity. After baseline measurements, the investigators will infuse angiotensin-(1-7) or saline for 30 minutes, with blood pressure and heart rate measured every 10 minutes. At the end of 30 minutes, blood samples will be collected and the rebreathing test will be repeated. The investigators will continue the angiotensin-(1-7) or saline infusion for an additional 2 hours while performing a hyperinsulinemic-euglycemic clamp to measure insulin sensitivity.
PROBLEM TO BE SOLVED: To provide a method for treatment and prevention of protozoiases by administrating a specific N-acetonylaryl amide derivative. SOLUTION: This method administers to a human or animal a compound shown by the formula (A is phenyl, pyridyl, oxazolyl, benzyl, alkyl or the like; R<1> and R<2> are each H, a 1-6C alkyl, 2-6C alkenyl or the like; and X, Y and Z are each H, a halo, cyano, thiocyano, isothiocyano or 1-6C alkyl sulfonyloxy), or an enantiomer, steric isomer or acid addition compound thereof. Its dosage to a human is 1 to 200 mg/day/kg for treatment and 0.5 to 100 mg/kg once a week for prevention. The medicine contains 0.1 to 99 wt.% of the compouns shown by the formula as the active ingredient. This method is effective to protozoiases caught by various protozoas, e.g. Giardia, Leishmania, Toxoplasma, Cryptosporidium, Entamoeba, microsporidi species.
PURPOSE:To obtain a new compound useful as a therapeutic agent for rheumatism, gingivitis and/or glomerulonephritis or a cancer metastatic inhibitor. CONSTITUTION:The objective compound of the formula or its pharmaceutically permissible salt, e.g. BE-19093. This compound of the formula is obtained by inoculating, e.g. Streptomyces sp. A19093 strain (FERM P-12506) or its mutant strain in a culture medium containing a nutrient source and aerobically cultured at pH4-8 and preferably 25-30 deg.C) for 12-168hr.
The application discloses an intelligent traditional Chinese medicine formula system and a construction method thereof, and relates to the technical field of intelligent equipment. The system comprises: the system comprises an information storage module, an information input module, an information processing module and an intelligent composition module; the information input module is electrically connected with the information processing module, the information processing module is electrically connected with the intelligent composition module, and the intelligent composition module is electrically connected with the information storage module. The intelligent formula output by the system provided by the application has a formula which accords with a specific syndrome differentiation theory and has a monarch, minister, assistant and guide structure, and the output is a traditional Chinese medicine formula in the traditional sense. The system provided by the application can comprehensively analyze the information of the traditional Chinese medicine diseases, the western medicine diseases, the symptoms and the syndromes provided by the user, and has universality. The system provided by the application can select the symptom composition model and/or the syndrome composition model when performing intelligent composition, and the traditional Chinese medicine characteristics are maintained. In addition, the system also realizes the combination of traditional Chinese medicine and western medicine.
A comparison of ischemic patients and non-ischemic controls will be done. The plasma level of sST2 will be withdrawn at baseline and 24-48 hours after the intervention in ischemic group. Then a study ischemic group will be divided into three subgroups; subgroup-1: single vessel disease, subgroup-2: two vessels disease and subgroup-3: multivessels disease. On admission, there will be a significant difference between the group of acute/chronic coronary syndrome cases and controls as regard sST2 plasma level or not. Moreover, the differences between the three ischemic subgroups at the baseline ST2 level will be assessed. The plasma sST2 level after PCI and the correlation between the acute change in pot-PCI sST2 level and the severity of ischemia by Modified Gensini Score (MGS) will be evaluated. The final question that will be answered by this study does the rapid impact of PCI on sST2 level will be mainly related to the severity of ischemia rather than left ventricular function or not.
The invention discloses herbal lozenges for treating ozostomia and a preparation method thereof, and belongs to the field of traditional Chinese medicines. The effective components of the herbal lozenges are prepared from the following raw materials: basil, chickweed, soapberry seeds, osmanthus fragrans, tulip, wood betony, alpinia katsumadai, daghestan sweetclover herb, syzygium aromaticum, the root of roxburgh rose, kumquat, wideleaf osbeckia root, semen armeniacae amarae, fructus forsythiae, field horsetail and ixeris chinensis. The herbal lozenges are prepared by the appropriate matching of selected medicinal materials, conform to the theories of the traditional Chinese medicine and pharmacy and the modern medicine and pharmacology, and have functions of drying damp and strengthening the spleen, nourishing the spleen and eliminating stagnation, clearing away heat and eliminating dampness as well as warming the stomach and preventing vomiting. Thus, the herbal lozenges are suitable for treating the ozostomia, dryness of the mouth, bitterness in the mouth, dyspepsia, inappetence, constipation, body odor and the like which are caused by various diseases and the like. The herbal lozenges are obvious in treatment effect without relapse after the curing and are safe, and cannot generate toxic and side effects. The normal work and the normal life of a patient during the taking of the herbal lozenges are not influenced. Therefore, the herbal lozenges are extremely effective and practical, thereby being worthy of wide popularizations and applications. The total effective rate of the herbal lozenges can reach 99.3%.
The invention provides a traditional Chinese medicine formula for lowering blood pressure. The traditional Chinese medicine formula comprises uncaria, common curculigo rhizomes, fructus aristolochiae, Chinese taxillus twigs, feather cockscomb seeds, great burdock achene, cassia seeds, capillary wormwood herb, elsholtzia rugulosa Hemsl., piper wallichii (Miq.) Hand.-Mazz. var hupehense (DC.) Hand.-mazz., celery juice, glutinous rice, pig bones, pure Baijiu and edible vinegar. The invention further provides a preparation method of the traditional Chinese medicine formula for lowering the blood pressure. On the basis of good blood pressure lowering effect of the uncaria and the celery juice, the traditional Chinese medicine formula added with the common curculigo rhizomes, the fructus aristolochiae, the Chinese taxillus twigs, the feather cockscomb seeds, the great burdock achene, the cassia seeds, the capillary wormwood herb, the elsholtzia rugulosa Hemsl. and the piper wallichii (Miq.) Hand.-Mazz. var hupehense (DC.) Hand.-mazz. is capable of lowering the blood pressure, stable and persistent in effect and free from any toxic or side effect. Additionally, the preparation method has the advantage that a patient can absorb decoction effectively after eating the glutinous rice containing the decoction.
Placebo nasal spray administered plus hydromorphone PCA . All study patients receive demand dosing patient-controlled analgesia (PCA) with intravenous hydromorphone. Initial loading dose 0.2 mg with demand doses of 0.2 mg and lockout interval of 15 minutes. There will be no basal dose and the 8-hour dose limit will be 6.4 mg.
Sexually transmitted infections (STIs) can produce long-term health problems. They are often linked to HIV, which can also be sexually transmitted, because both occur in the same populations and because STIs and HIV interact biologically. Having an STI other than HIV can increase the risk of HIV acquisition and transmission as well as negatively impact HIV progression. The population of people who go to clinics specializing in STIs are particularly at risk of engaging in risky sexual behaviors and having poor health outcomes-like infection with an STI. This study will test the effectiveness of using an educational DVD to reduce incidence of risky sexual behaviors and STI acquisition, including risk of HIV, and to improve overall health.

Participation in this study will involve two phases. In Phase 1, participants will complete both computerized and paper surveys and watch an educational DVD. The educational DVD may include information on diet, physical activity, sleep, smoking, STIs, and stress. Participants will be recruited from among people who are already going to the clinic, and participation will add approximately 1.5 hours to their visits. In Phase 2, participants will be asked to complete four follow-up visits occurring 3, 6, 9, and 12 months after Phase 1. During these follow-up visits, participants will complete a 45-minute computerized survey similar to that in Phase 1 and provide urine and throat samples for STI testing. All surveys will assess health-related thoughts, feelings, and behaviors, including sexual behaviors. Participants will be compensated for completing Phase 1 and each visit in Phase 2.
Approximately 20% of head and neck squamous cell carcinomas (HNSCCs) exhibit reduced methylation on lysine 36 of histone H3 (H3K36me) due to mutations in histone methylase NSD1 or a lysine-to-methionine mutation in histone H3 (H3K36M). Whether such alterations of H3K36me can be exploited for therapeutic interventions is still unknown. Here, we show that HNSCC models expressing H3K36M can be divided into two groups: those that display aberrant accumulation of H3K27me3 and those that maintain steady levels of H3K27me3. The former group exhibits reduced proliferation, genome instability, and heightened sensitivity to genotoxic agents like PARP1/2 inhibitors. Conversely, H3K36M HNSCC models with constant H3K27me3 levels lack these characteristics unless H3K27me3 is elevated by DNA hypomethylating agents or inhibiting H3K27me3 demethylases KDM6A/B. Mechanistically, H3K36M reduces H3K36me by directly impeding the activities of the histone methyltransferase NSD3 and the histone demethylase LSD2. Notably, aberrant H3K27me3 levels induced by H3K36M expression are not a bona fide epigenetic mark because they require continuous expression of H3K36M to be inherited. Moreover, increased sensitivity to PARP1/2 inhibitors in H3K36M HNSCC models depends solely on elevated H3K27me3 levels and diminishing BRCA1- and FANCD2-dependent DNA repair. Finally, a PARP1/2 inhibitor alone reduces tumor burden in a H3K36M HNSCC xenograft model with elevated H3K27me3, whereas in a model with consistent H3K27me3, a combination of PARP1/2 inhibitors and agents that up-regulate H3K27me3 proves to be successful. These findings underscore the crucial balance between H3K36 and H3K27 methylation in maintaining genome instability, offering new therapeutic options for patients with H3K36me-deficient tumors.
BACKGROUND: As an innovative lipid parameter, NHHR (the ratio of non-high-density lipoprotein cholesterol to high-density lipoprotein cholesterol) can serve as a valuable tool for assessing cardiovascular disease risk. Nevertheless, the relationship between NHHR and the risk of kidney stones remains unexplored.
METHODS: A cross-sectional survey utilized data from the National Health and Population Survey (NHANES) database in the United States spanning from 2007 to 2018. Distinct statistical analyses were applied, including weighted logistic regression, stratified and interaction analysis and restricted cubic spline curve (RCS) models, to examine the correlation between NHHR and the incidence of kidney stones.
RESULTS: This analysis encompassed 24,664 participants, with 9.63% reporting incidents of kidney stones. Following multivariate logistic regression and comprehensive adjustments, participants in NHHR quartile 4 (OR 1.34; 95% CI 1.12, 1.60, P < 0.01) exhibited a significantly increased risk of kidney stones compared to those in NHHR quartile 1 (Q1). The RCS result further illustrated a non-linear correlation between NHHR and the incidence of kidney stones. The result of subgroup analysis manifested that participants without diabetes had a higher risk of kidney stones when measured high NHHR levels compared those with diabetes (p for interaction < 0.05).
CONCLUSION: Elevated NHHR levels were found to be associated with an increased risk of kidney stones. Based on these findings, NHHR appears to be a promising predictive indicator for the occurrence of kidney stones.
PROBLEM TO BE SOLVED: To obtain an inexpensive immunoactivator which has immunopotentiation and antitumor activities and is free from adverse effects, e.g. acute toxicity, mutagenicity and the like, by including a specific extract (purified product) from Lyophyllum decastes (Fr.) Sing. as an active ingredient. SOLUTION: This immunoacrtivator is obtained by including an extract (purified product) from Lyophyllum decastes (Fr.) Sing. which contains polymeric polysaccharides as an active ingredient. Lyophyllum decastes (Fr.) Sing. is a mushroom belonging to the genus Lyophyllum of the family Tricholomaceae. As the Lyophyllum decastes (Fr.) Sing., the fungal strain, 'Kameyama No. 1' (nursery law form registration application number 6811) of Lyophyllum decastes (Fr.) Sing. capable of artificially cultivating is preferably used. As the culture medium component for cultivation, the component containing chitins (crab shells), beer yeast lees or the like known as substances having biological response modifier-like effect is favorable. The extract from Lyophyllum decastes (Fr.) Sing. is obtained by extracting fruit bodies of Lyophyllum decastes (Fr.) Sing. with hot water.  As the active ingredient, the component which is a water-soluble yellowish grown powder and contains saccharides and proteins in amounts of 30-90 wt.% and 5-15 wt.%, respectively, is favorable.
Photobiomodulation therapy sessions will be carried out in the physiotherapy environment on the University, once a week, for 08 consecutive weeks in the same day of the institution's standard physiotherapy session that the patient already uses regularly (not linked to the study). will be transcutaneously, punctual application of the LED in the medial and lateral gastrocnemius muscles of the right lower limb, in contact mode, 3J/cm2, with a 850nm wavelenght (01 point per gastroc, muscle). All patients will received the PBM protocol + the standard physiotherapy rehabilitation treatment of the institute not linked to the study, and which the patient already uses regularly.
The predictive value of the extent of peri-operative lymph node (LN) sampling in relation to disease relapse in patients with pulmonary carcinoid (PC) is unknown. Furthermore, post-surgery follow-up recommendations rely on institutional retrospective studies with short follow-ups. We aimed to address these shortcomings by examining the relation between LN sampling and relapse in a population-based cohort with long-term follow-up. By combining the Dutch nationwide pathology and cancer registries, all patients with surgically resected PC (2003-2012) were included in this analysis (last update 2020). The extent of surgical LN dissection was scored for the number of LN samples, location (hilar/mediastinal), and completeness of resection according to European Society of Thoracic Surgeons (ESTS) guidelines. Relapse-free interval (RFI) was evaluated using Kaplan Meier and multivariate regression analysis. 662 patients were included. The median follow-up was 87.5 months. Relapse occurred in 10% of patients, mostly liver (51.8%) and locoregional sites (45%). The median RFI was 48.1 months (95% CI 36.8-59.4). Poor prognostic factors were atypical carcinoid, pN1/2, and R1/R2 resection. In 546 patients LN dissection data could be retrieved; at least one N2 LN was examined in 44% and completeness according to ESTS in merely 7%. In 477 cN0 patients, 5.9% had pN1 and 2.5% had pN2 disease. In conclusion, relapse occurred in 10% of PC patients with a median RFI of 48.1 months thereby underscoring the necessity of long-term follow-up. Extended mediastinal LN sampling was rarely performed but systematic nodal evaluation is recommended as it provides prognostic information on distant relapse.
Mutations in the transcription factors encoded by PHOX2B or LBX1 correlate with congenital central hypoventilation disorders. These conditions are typically characterized by pronounced hypoventilation, central apnea, and diminished chemoreflexes, particularly to abnormally high levels of arterial PCO2. The dysfunctional neurons causing these respiratory disorders are largely unknown. Here, we show that distinct, and previously undescribed, sets of medullary neurons coexpressing both transcription factors (dB2 neurons) account for specific respiratory functions and phenotypes seen in congenital hypoventilation. By combining intersectional chemogenetics, intersectional labeling, lineage tracing, and conditional mutagenesis, we uncovered subgroups of dB2 neurons with key functions in (i) respiratory tidal volumes, (ii) the hypercarbic reflex, (iii) neonatal respiratory stability, and (iv) neonatal survival. These data provide functional evidence for the critical role of distinct medullary dB2 neurons in neonatal respiratory physiology. In summary, our work identifies distinct subgroups of dB2 neurons regulating breathing homeostasis, dysfunction of which causes respiratory phenotypes associated with congenital hypoventilation.
Particles of a primary emulsion of an oil in a hydrophilic liquid containing a thickening agent are encapsulated by a process wherein the primary emulsion is dispersed to form a secondary emulsion in a coacervating solution comprising a coacervating agent and an aqueous sol or solution of a gelable hydrophilic colloid at a temperature above the gel point of the colloid which is caused to coacervate and thus to coat the particles of the primary emulsion with a coating that may subsequently be hardened. Suitable thickening agents are materials which are substantially insoluble in the oil phase of the primary emulsion and which cause the external phase of the primary emulsion to have a surface which is lipophilic or at least less hydrophilic than water, e.g. acacia, tragacanth, methyl- and carboxymethyl-cellulose, magnesium aluminium silicate, polyglycols, glycerin and syrups.  Suitable colloids are gelable, hydrophilic colloids, e.g. gelatine (preferred), agar-agar, albumin, alginates, casein, pectins, starch and fibrinogen.  The coacervating agent may be an electrolyte e.g. salts having alkali or alkali-metal cations and organic or inorganic anions or a water-soluble liquid in which the coacervating colloid is less soluble in water.  A conventional emulsifying agent may be used in the preparation of the primary emulsion and the coacervating solution may contain a thickening agent.  Either or both phases of the primary emulsion may contain dissolved or suspended materials which confer on the product of the invention properties which render them useful as bactericides, fertilizers, plant growth hormone preparations, pesticides, additives to pre-mixed foods, e.g. vitamin preparations suitable for addition to dry cereal preparations, cosmetic ingredients and pharmaceutical preparations for oral, topical and injectable application, particularly for sustained or delayed release of the active material. Details of the processes used are given.  Specification 751,600 is referred to.
Dysmenorrhea, characterized by painful cramps of the uterus during menstruation. It affects up to 95% of menstruating women. Dysmenorrhea is classified as primary and secondary dysmenorrhea. Primary dysmenorrhea is defined as menstrual cramping pain that occurs immediately before or during menstruation in the absence of any pelvic pathology. The pain commonly starts within 3 years of menarche (the first menstrual period). Prevalence of primary dysmenorrhea varies from between 16 to 91% in reproductive aged women. Primary dysmenorrhea is the leading women hood problem that affects 90% of adolescent girls. Its prevalence decreases with increasing age in a large percentage of sufferers.

A study conducted in China concluded that nurse-managed education program improved adolescent girls' menstrual knowledge, promoted a more positive attitude, encouraged confidence, and improved pain relief practice. Another study conducted in Taiwan showed that the prevalence in dysmenorrhea in female adolescents was high, but they were lacking in dysmenorrhea related self-care knowledge. An Australian study concluded that the prevalence and impact of dysmenorrhea on Grade 11 and 12 girls is high, girls need more education on this area to prevent unnecessary suffering and interruption to school routine as they lack knowledge of and experience with effective treatment. A cross-sectional, internet-based survey was conducted, concluded that one in 3 women quit daily activities owing to menstrual symptoms. Half of all women did not mention menstrual complaints being the reason for transferring tasks in a family setting. However, considering the impact of menstrual symptoms on daily activities in a large group of women, it is time to open the societal dialogue and improve education for both patients and doctors.
The safety and effectiveness in pediatric patients less than 7 years of age have not been established.

Safety and effectiveness of duloxetine have not been established in pediatric patients less than 18 years of age with MDD.

Decreased appetite and weight loss have been observed in association with the use of SSRIs and SNRIs. Perform regular monitoring of weight and growth in children and adolescents treated with an SNRI such as duloxetine [see Adverse Reactions (6.11)].

Information describing two additional clinical studies in which efficacy was not demonstrated in patients ages 7 to 17 years is approved for Eli Lilly and Company, Inc.’s duloxetine delayed-release capsules. Other pediatric use information for patients ages 7 to 17 years is approved for Eli Lilly and Company, Inc.’s duloxetine delayed-release capsules. However, due to Eli Lilly and Company, Inc.’s marketing exclusivity rights, this drug product is not labeled with that pediatric information.

Animal Data — Duloxetine administration to young rats from post-natal day 21 (weaning) through post-natal day 90 (adult) resulted in decreased body weights that persisted into adulthood, but recovered when drug treatment was discontinued; slightly delayed (~1.5 days) sexual maturation in females, without any effect on fertility; and a delay in learning a complex task in adulthood, which was not observed after drug treatment was discontinued. These effects were observed at the high dose of 45 mg/kg/day (2 times the MRHD, for a child); the no-effect-level was 20 mg/kg/day (≈1 times the MRHD, for a child).